Literature DB >> 6132132

Carbamazepine-induced non-hereditary acute porphyria.

A A Yeung Laiwah, W G Rapeport, G G Thompson, G J Macphee, M F Philip, M R Moore, M J Brodie, A Goldberg.   

Abstract

Acute intermittent porphyria has hitherto been recognised as an autosomal dominant inborn error of haem metabolism characterised by a depressed activity of the enzyme uroporphyrinogen I synthase (URO.S). A case of non-hereditary acute porphyria, similar to acute intermittent porphyria, following treatment of epilepsy with carbamazepine is reported. Subsequent measurements of erythrocyte URO.S activity in a group of epileptic patients treated with various combinations of anticonvulsant drugs suggest that carbamazepine exerts a direct suppressant effect on URO.S in addition to its indirect enzyme-inducing properties.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6132132     DOI: 10.1016/s0140-6736(83)91850-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

Review 1.  The risk-benefit ratio of anticonvulsant drugs.

Authors:  M J Eadie
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

2.  Effect of stanozolol on delta-aminolaevulinic acid synthase and hepatic monooxygenase activity in man and rat.

Authors:  G G Thompson; M Small; G D Lowe; C D Forbes; B K Park; G Scobie; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  The effects of chronic carbamazepine treatment of haem biosynthesis in man and rat.

Authors:  G M McGuire; G J Macphee; G G Thompson; B K Park; M R Moore; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Effects of cimetidine on carbamazepine auto- and hetero-induction in man.

Authors:  G J Macphee; G G Thompson; G Scobie; E Agnew; B K Park; T Murray; K E McColl; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

5.  Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity.

Authors:  A L Herrick; K E McColl; M R Moore; M J Brodie; A R Adamson; A Goldberg
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.